|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
gptkb:FDA
2000
|
|
gptkbp:ATCCode
|
L01XC05
|
|
gptkbp:blackBoxWarning
|
hepatotoxicity
veno-occlusive disease
|
|
gptkbp:brand
|
Mylotarg
|
|
gptkbp:CASNumber
|
220127-57-1
|
|
gptkbp:contraindication
|
hypersensitivity to gemtuzumab ozogamicin
|
|
gptkbp:developedBy
|
gptkb:Wyeth
|
|
gptkbp:eliminationHalfLife
|
62 hours
|
|
gptkbp:form
|
lyophilized powder for injection
|
|
gptkbp:hasComponent
|
ozogamicin
gemtuzumab
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
gemtuzumab ozogamicin
|
|
gptkbp:indication
|
newly diagnosed CD33-positive AML
relapsed or refractory CD33-positive AML
|
|
gptkbp:KEGGID
|
D04124
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
CD33 antigen
|
|
gptkbp:marketedAs
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
induces DNA breaks via calicheamicin
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:pregnancyCategory
|
D
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:DB01008
CHEMBL1201587
11759629
|
|
gptkbp:reapproved
|
2017
|
|
gptkbp:riskFactor
|
infections
hemorrhage
severe myelosuppression
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
hepatotoxicity
neutropenia
thrombocytopenia
hemorrhage
infusion reactions
|
|
gptkbp:target
|
gptkb:CD33
|
|
gptkbp:UNII
|
QZP2JZ6B5K
|
|
gptkbp:usedFor
|
gptkb:acute_myeloid_leukemia
|
|
gptkbp:withdrawn
|
2010
|
|
gptkbp:bfsParent
|
gptkb:CD33
|
|
gptkbp:bfsLayer
|
7
|